Therefore , we conclude that MeCCNU is not an essential component of effective postoperative combined modality treatment of adjuvant rectal cancer and should not be included in future treatment regimens .
Although the superiority of combination radiotherapy and chemotherapy with fluorouracil(5-FU) and semustine (MeCCNU) was clearly shown in terms of both disease-free survival and , subsequently , overall survival , the clinical impact of such treatment was tempered by the inclusion of MeCCNU in an adjuvant setting .
